All posts by medical

The path to deeper connections, even amidst a pandemic | Penn Today – Penn Today

For the past year, staying physically apart from others was crucial to keeping everyone safe in the face of a brand new, deadly virus. Though necessary, the social distancing also amplified an already troubling fact: Rates of loneliness have been rising for the past several decades in the United States.

Even before the pandemic, the increase in loneliness has been striking, says Edward Brodkin, a psychiatrist in Penns Perelman School of Medicine. And then along comes the pandemic, which of course separated us even more.

That separation made everyday communication and interaction challenging, says Ashley Pallathra, a clinical psychology doctoral candidate at The Catholic University of America and a former member of Brodkins lab. In person, wearing masks covers our ability to communicate through facial expressions, she says. And from the quarantining and isolation, people started to feel the loss of intimate, close relationships but also the loss of people on the commute to work or in the local coffee shop.

In their new book, Missing Each Other: How to Cultivate Meaningful Connections, Brodkin and Pallathra explore the science of attunement, the process necessary for relationships to move beyond the surface level to deeper and sometimes more emotional connections.

Broadly speaking, attunement describes an awareness thats both internal and external facing, of ones own state of mind and body and that of another person. Attunement involves an ability to get in sync with others, to engage with them effectively, not just in a single moment but over an interactions twists and turns.

It shows up in many aspects of life beyond personal relationships, for example, in team sports or music ensembles. Although its obviously most important in close relationships, it can also be helpful in our day-to-day interactions, Brodkin says. We could communicate better so were not talking past each other.

To elucidate this intricate process of connection, Brodkin and Pallathra propose a framework for understanding attunement, which they argue consists of four components: relaxed awareness, listening, understanding, and mutual responsiveness. They offer exercises for readers to develop each skill.

The idea for the book grew out of work from Brodkins lab, which focuses on autism, social neuroscience, and how the brain functions in social interactions. He and Pallathra were collaborating on a project aimed at supporting adults on the autism spectrum in their social functioning. The further into it they got, the more they realized they wanted their project to go beyond traditional social skills.

That type of program often includes suggested social scripts and rules, which can be useful sometimes, but they are also limited, Brodkin says. It dawned on us that we were really trying to teach attunement. Then we thought, maybe this program is not only useful for adults on the autism spectrum. Maybe it could be helpful for any of us. Its a difficult skill but one that, if you understand and develop it, can have a huge payoff.

Missing Each Other lays out the four components of attunement sequentially, with each one building on the last:

This means being aware of yourself as well as your environment, being aware of how you feel, your emotions, your reactions, but also aware of whats going on around you, of the conversation youre having, of the message another person is trying to communicate, all while staying fairly relaxed, Pallathra says. She describes it as a type of mindfulness involving awareness and emotional self-regulation, rather than a focus on emptying the mind.

This second step isnt just about hearing the words another person is saying, but broader, taking in all social cues from the pacing and tone of speech to body language and facial expression. Its about paying attention and synchronythe subconscious mirroring that takes place in a conversation, like when one person nods or crosses his legs after the other does. Its also about resonating with the other person emotionally, in other words, having emotional empathy.

This entails understanding another persons perspective but also your own, Pallathra says. There are a lot of pitfalls to understanding, things that get in the way like your biases and assumptions, your reactivity. Being able to recognize those will help create a balance between regulating yourself and staying open to the other person.

This is the natural back and forth of a lively and fulfilling conversation or interaction. Partners meet in the middle, responding to each others moods. Its paradoxical to think of meeting the other person where they are as a way of being powerful and getting your message across, Brodkin says. But if you cultivate this art of being open to the other person, listening, understanding, and initiating a connection where the other person is mentally and emotionally, youre in a better position to communicate what you want to communicate, too.

Brodkin and Pallathra offer a set of exercises that may help enhance each skill. For instance, stretches to release physical tension and mindfulness of posture and breath can help develop relaxed awareness. For listening, they suggest motor synchrony exercises based on tai chi or a simple how-was-your-day conversation.

Ask someone to tell you about their day, Brodkin explains. Then for three to five minutes, really try to listen. Give the other person an opportunity to talk. Focus on what shes communicating and occasionally check back with yourself. Take a breath to regulate yourself and then refocus on the other person. Practice regularly and you can develop this capacity, much like you develop your biceps at the gym.

All of these exercises can be adapted for at-home use, he adds. Develop these on your own or with people in your social bubble, so when we do come back together, well be better communicators.

Edward Brodkin is co-director of the Autism Spectrum Program of Excellence at the University of Pennsylvania. He is also founder and director of the Adult Autism Spectrum Program and an associate professor of psychiatry at the Perelman School of Medicine.

Ashley Pallathra is a clinical researcher and therapist and is currently pursuing her Ph.D. in clinical psychology at The Catholic University of America in Washington, D.C. She is a Penn alumna and former member of the Brodkin lab.

Read the original:
The path to deeper connections, even amidst a pandemic | Penn Today - Penn Today

Blumberg to Speak on Teen Suicide Prevention Panel – Yale School of Medicine

Hilary Blumberg, MD, John and Hope Furth Professor of Psychiatric Neuroscience and Professor of Psychiatry, and in the Child Study Center and of Radiology and Biomedical Imaging, will participate in a panel discussion Sunday, April 11, 2021, related to the prevention of youth suicide.

The panel will follow the screening of the documentary My Ascension, a feature-length film that chronicles the experience of Emma Benoit, a then-16-year-old cheerleader who survived a suicide attempt in 2017 the summer before her senior year in high school. Her attempt resulted in a spinal cord injury that left her paralyzed but also helped her find faith and purpose and put her on a mission to help prevent youth suicide.

The film also highlights the stories of two young people who did not survive their suicide attempts. Viewers will hear from their families, friends, school officials, and suicide prevention experts about the devastating effects of suicide and what can be done to prevent it.

The movie and panel discussion will be from 6:00 to 9:00 pm April 11. Registration is free.

The panel will be moderated by Gregg Dicharry, director of My Ascension. In addition to Blumberg it will feature Benoit; actress Jessica Hecht, Olympic gold medalist Samantha Livingstone, and Gillian Anderson, founder of My Friend Abby, the events host.

Anderson created My Friend Abby after the death of her 15-year-old daughter, Abby, by suicide. The non-profit organizations mission is to empower youth and young adults to actively create peer to peer connections through grants that improve mental and emotional health.

Blumberg directs the Mood Disorders Research Program at Yale. The organization brings together a multi-disciplinary group of scientists to study the genetic, developmental, and environmental factors that cause mood disorders to develop new methods for early detection, more effective interventions, and prevention of the disorders and their associated high risk for suicide. This research includes the use of new state-of-the-art brain scanning methods. The program trains young scientists to be new leaders in the field.

Read this article:
Blumberg to Speak on Teen Suicide Prevention Panel - Yale School of Medicine

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas…

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

PARIS AND CAMBRIDGE, MA April 9, 2021 Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofis research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones. We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population, said Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi. We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions.

Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells inside the body. The technology delivers mRNA cargos selectively to designated types of cells in the body, with initial applications targeting specific types of immune cells. The in vivo approach is designed to provide similar efficacy to current ex vivo (outside the body) approaches where immune cells are genetically modified to enhance their therapeutic properties (such as chimeric antigen receptor [CAR]-expressing T-cells), with the potential for improved safety, outpatient dosing, and repeat dosing. Currently, Tidal Therapeutics has ongoing pre-clinical programs including in vivo re-programming of T cells or other types of immune cells for cancer indications.

Teaming up with Sanofi gives us the opportunity to further develop our unique platform and rapidly apply it to ultimately help patients across a range of diseases, said Ulrik Nielsen, President and CEO, Tidal Therapeutics.

About Tidal TherapeuticsTidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases. The company was seeded by Mission BioCapital, and joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundations venture philanthropy, MRL Ventures, and AbbVie Ventures.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Investor Relations Contacts ParisEva Schaefer-JansenArnaud Delepine

Investor Relations Contacts North AmericaFelix LauscherFara BerkowitzSuzanne Greco

IR main line:Tel.: +33 (0)1 53 77 45 45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact

Read more:
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas...

Genomic testing services in pathology & immunology department to be expanded Washington University School of Medicine in St. Louis – Washington…

Visit the News Hub

Changes aimed at improving diagnosis of cancer, inherited diseases

The Department of Pathology & Immunology at Washington University School of Medicine in St. Louis is reorganizing and expanding its genomic medicine testing services to take advantage of advances in genetic and genomic sciences and improve clinical care.

Genetic and genomic testing is driving advances in precision medicine. Such testing provides the data that, when combined with information about disease status and environmental factors, enable doctors to move away from one-size-fits-all treatment plans to personalized therapies tailored to individual needs.

The Department of Pathology & Immunology at Washington University School of Medicine in St. Louis is reorganizing and expanding its genomic medicine testing services to take advantage of advances in genetic and genomic sciences and improve clinical care. Several new tests for cancer and inherited diseases are in the works. The department also is redesigning its website to make it easier for physicians to quickly identify the most appropriate tests for their patients.

As part of the reorganization, the department is establishing two new sections: a molecular oncology section, led by Eric Duncavage, MD, and an inherited diseases section, headed by Jonathan Heusel, MD, PhD.

The School of Medicine has been at the forefront of genetics research for many years, including leadership in whole genome sequencing, saidRichard Cote, MD, the Edward Mallinckrodt Professor and head of the Department of Pathology & Immunology. We have long had a major stake in translating these discoveries into clinically actionable tests to better define prognosis and treatment for a wide variety of diseases. We are delighted that Jon Heusel and Eric Duncavage, widely recognized for their research, are leading the effort to enhance the departments genetic and genomic testing services.

A wide variety of different mutations can give rise to cancer, and the specific mutations carried by a particular tumor affect its susceptibility to a particular treatment. These mutations also can be used to track a tumor during therapy to determine how it is responding to therapy. Clinical cancer genomics aims to use information on tumor mutations to help identify the therapies most likely to benefit the patient and avoid those least likely to help.

Duncavage

Duncavage and his Washington University colleagues recently developed a diagnostic test, ChromoSeq, for blood cancers, based on sequencing the whole genome. This comprehensive analysis has greater sensitivity than traditional testing, providing additional information that could help clinicians assess each patients risk of severe disease and choose the best treatment plan. The test was evaluated in a clinical trial of patients treated at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine. Results of that trial were published in March in The New England Journal of Medicine. ChromoSeq whole genome sequencing for blood cancers will be available as a clinical test through the Department of Pathology & Immunology.

Until recently, we could only analyze a limited set of genes or chromosomes because whole genome sequencing was too expensive for routine clinical use, Duncavage said. But recent advances in sequencing technologies and data analysis techniques have driven down the cost of whole genome sequencing in both time and resources. We showed that the technology could be used for blood cancers, and we are working on applying it to other kinds of cancers.

In addition, Heusel and Duncavage are spearheading an effort to develop tests to identify people with an inherited predisposition to cancer. Most famously, variations in the BRCA1 and BRCA2 genes increase the risk of breast and ovarian cancer, but dozens of other genes have been linked to a range of cancers. In the interest of efficiency, the tests under development are based on sequencing only the 2% of the genome that codes for proteins. This tiny fraction of the genome known as the exome is where nearly all mutations associated with disease risk are found.

Heusel

As chief of the inherited diseases section, Heusel will oversee the development and operation of tests for rare genetic diseases. Some of the people most in need of whole genome testing are babies born with mysterious ailments that appear to have genetic causes. Sequencing an affected newborns entire genome and often the genomes of both parents, too can be the fastest way to find an explanation for a babys condition.

Heusel and colleagues also are working on an improved test for disorders of somatic mosaicism, a group of conditions characterized by mutations in some cells but not others. Patients can have a wide range of symptoms, including overgrowth of one part of the body, such as the hand; skin spots or rashes; and abnormal tangles of blood vessels. The symptoms depend not only on what mutation has occurred but in which cells it has occurred. The researchers are building a faster, cheaper test that will allow more genes and more conditions to be screened.

Genetic testing particularly what we call next-generation sequencing, which involves sequencing dozens or hundreds of genes or whole exomes or whole genomes its transforming medicine, transforming the way we understand the basis of disease, how to diagnose it and how to treat it, Heusel said. What were really trying to do in the department now is make it easier for clinicians to take advantage of all the new genetic and genomic diagnostic tools that are becoming available.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, consistently ranking among the top medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Link:
Genomic testing services in pathology & immunology department to be expanded Washington University School of Medicine in St. Louis - Washington...

Assistant/Associate/Full Professor of Veterinary Microbiology and Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 250949 – Times Higher…

Job Description

The United Arab Emirates University's College of Food & Agriculture invites applications for a faculty position in Microbiology with experience in Immunology and the One Health approach for the Department of Veterinary Medicine. Qualified candidates at all levels will be considered at a rank commensurate with academic accomplishments. Candidates are expected to have an understanding of veterinary education that will enable them to teach and coordinate courses in veterinary microbiology (virology, bacteriology, mycology) and immunology at both undergraduate and postgraduate levels as well as advise and mentor students. They should have a proven track record of demonstrable research capability that will enable the candidate to develop and sustain an internally and/or externally funded research program in his/her area of expertise and publish his/her research findings in international peer-reviewed scientific journals. The candidate will contribute to admissions, examining and assessment as well as academic administration in both the Department and the College, and actively promote the growth of the UAE University engaging in interdisciplinary collaboration with other UAEU colleges, e.g. College of Medicine and Health Sciences, College of Science, under the theme of One Health. The application package should include a cover letter, a detailed resume, a brief description of teaching philosophy and current/future research activities, as well as courses taught. English is the language of instruction and communication. Screening of applications will continue until the position is filled.

Minimum Qualification

Applicants must have an earned doctorate in Infectious Diseases, Virology, Bacteriology, Mycology, Immunology or similar field. The ability to teach undergraduate courses is a must. Industrial and professional experience is a plus. Good interpersonal and English oral and written communication skills are required, as is the ability to work with others in a diverse collegial team atmosphere.

Preferred Qualification

Candidates with a degree in veterinary medicine or comparable professional degree with documented accomplishments in teaching, research, and service are preferred. Additional qualifications of innovative and dynamic teaching or other professional skills relevant to a faculty role are desirable. Other evidence of working in One Health-related teaching and/or research especially in the Middle East and North Africa region as well as engagement in international-quality research, with publications and other participation in research activities commensurate with stage of career as well as a track record of securing research funding. Experience with AVMA accreditation requirements, and knowledge of innovative curriculum development and implementation is a plus.

Expected Skills/Rank/Experience

Rank and salary commensurate with accomplishments, expertise and experience. English fluency required. One Health-related teaching and/or research experience. Innovative and dynamic teaching or other professional skills. Record of research grantmaking and publications in international peer-reviewed journals.

Special Instructions to Applicant

Informal enquiries may be made to Prof Arve Lee Willingham (Chair, Department Veterinary Medicine) - awillingham@uaeu.ac.ae

Division College of Food & Agriculture-(CFA)Department Veterinary Medicine - (CFA)Job Close Date open until filledJob Category Academic - Faculty

See more here:
Assistant/Associate/Full Professor of Veterinary Microbiology and Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 250949 - Times Higher...

IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology – Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--IM Therapeutics, Inc., a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases, announced today that David Alleva, Ph.D., has joined its management team as Vice President, Immunology. Dr. Alleva is an immunologist with deep experience in R&D in autoimmunity and infectious disease spanning 22 years and across early-stage biotech, foundations, and clinical-stage biopharmaceutical organizations.

IM Therapeutics IMT-HALT platform enables the development of oral small molecule drugs to block HLA gene variants as the earliest triggers of autoimmunity. The Companys lead drug candidate, IMT-002, is in a Phase 1b study in type 1 diabetes (T1D) in patients genetically preselected for HLA-DQ8. HLA-DQ8 significantly increases the risk for T1D and is present in 60% of T1D patients.

I am excited to welcome David to our leadership team and impressed by his work in novel approaches in T1D and the autoimmune spectrum, said Nandan Padukone, Ph.D., CEO of IM Therapeutics. David broadens our expertise at a pivotal time as we advance our lead program in T1D through Phase 1 clinical trials and progress our additional programs. Davids advocacy for new ways to treat T1D and his immunotherapy drug development experience will be tremendous assets to the company as we expand our autoimmune-targeted pipeline.

Dr. Alleva has been in senior R&D management positions, most recently at Akston Biosciences where he led immunotherapy development for T1D and a COVID-19 vaccine program. Previously, he led several R&D programs with ADiTx in T1D, managed portfolio programs at JDRF, and helped advance drug development of small-molecules, biologics, and vaccine therapeutics at Emergent BioSolutions, Hollis-Eden Pharmaceuticals, XOMA, and Neurocrine Biosciences.

Dr. Alleva earned a Ph.D. in immunology from the Virginia Polytechnic Institute and State University and performed postdoctoral autoimmune disease research at Boston University Medical Center. He has authored more than 30 peer-reviewed publications, has chaired immunology conferences, and is on the Editorial Board for the Biomedicines MDPI journal.

HLA drug targeting holds great promise and I am very excited by the progress made by IM Therapeutics to tap into this genetically-directed approach for T1D and other autoimmune diseases, said Dr. Alleva. I look forward to joining this dynamic team and bringing forward new personalized medicines to treat the underlying biology of autoimmunity.

About IMT-002

IMT-002, the lead drug candidate of IM Therapeutics, is the first oral genetically targeted drug candidate to be tested in T1D patients, an incurable autoimmune disorder that affects nearly 1.6 million people in the United States. IMT-002 completed a Phase 1a study in 2020 and is currently completing a Phase 1b study in T1D patients preselected for the HLA-DQ8 gene variant. IMT-002 is designed to block HLA-DQ8 to prevent the immune system from attacking insulin-producing beta cells, thereby preserving function in newly diagnosed patients, and is being investigated as a once- or twice-daily drug candidate. Previous studies of a tool drug, L-methyldopa, which is FDA-approved for treating hypertension, in a Phase 1b study, showed effective inhibition of HLA-DQ8 activity in new onset type 1 diabetes patients who had the HLA-DQ8 gene variant. Several in vivo IND-enabling studies indicate that IMT-002, which unlike the tool drug, is not metabolized physiologically, has more potency to block HLA-DQ8 activity and a favorable safety profile.

About IM Therapeutics

IM Therapeutics is a clinical-stage company pioneering personalized, oral medicines that target human leukocyte antigen (HLA) gene variants to treat the root cause of autoimmune diseases. The Companys IMT-HALT platform enables the development of small molecule drugs using in silico docking of millions of compounds into pockets of an HLA variant where self-antigens may bind to trigger autoimmunity. Selected drug hits are then optimized using proprietary structure-based design and activity screening with cell-based assays for specificity of HLA inhibition. Lead drugs developed against an HLA variant have the ability to block a series of self-antigens and therefore the potential to treat a range of autoimmune diseases related to a selected HLA. The Company is building a broad HLA-targeted pipeline in autoimmune disorders including type 1 diabetes, celiac disease, and lupus. Learn more at http://www.IMTherapeutics.com.

See the original post here:
IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology - Business Wire

LSU Health Shreveport awarded over $10.5 million for a NIH COBRE research grant focused on better understanding the immune system and how diseases…

LSU Health Shreveport has received a 5-year grant for $10,529,128 from the National Institutes of Health (NIH) to establish a new Center of Biomedical Research Excellence or COBRE. The grant has two-five year renewal options.

Funding from the COBRE grant will be utilized to create the Center for Applied Immunology and Pathological Processes (CAIPP). Dr. Andrew D. Yurochko, Professor and Carroll Feist Endowed Chair of Viral Oncology; Vice-Chair of Microbiology and Immunology, and Director of the Center of Excellence for Emerging Viral Threats is the principal investigator for the grant and will be the director of the new center. Serving as senior faculty members and directors or chairs of the key COBRE cores of this new Center for Applied Immunology and Pathological Processes (CAIPP) are:

Dr. Rona S. Scott, Associate Professor and Mingyu Ding Professor of Microbiology and Immunology (will serve as Director of the Bioinformatics/Modeling Core),

Dr. Matthew D. Woolard, Associate Professor and OCallaghan Family Endowed Professor in Microbiology (will serve as Director of the Immunophenotyping Core), and

Dr. Martin J. Sapp, Department Chair and Professor of Microbiology and Immunology and Willis Knighton Chair of Molecular Biology (will Chair the Junior Faculty Mentoring Committee).

Serving as the first of the key junior research faculty for the CAIPP are:

Dr. Xiaohong Lu, Assistant Professor of Pharmacology, Toxicology and Neuroscience,

Dr. Ana Dragoi, Assistant Professor of Molecular and Cellular Physiology, and

Dr. Monica Cartelle Gestal, Assistant Professor of Microbiology and Immunology.

This third COBRE at LSU Health Shreveport will provide an interactive training and research environment for young investigators in the field of immunology, as well as allow them to receive the mentorship and guidance needed to increase their competitiveness for national funding. The goal of all COBRE grants is to grow, recruit and retain new talent; expand existing research; and develop robust infrastructure that encourages statewide collaboration.

Read more:
LSU Health Shreveport awarded over $10.5 million for a NIH COBRE research grant focused on better understanding the immune system and how diseases...

Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development, Upcoming Webinar Hosted by Xtalks – PR Web

This talk will outline when to consider different I&I assay services and the regulatory and scientific considerations for these that will influence the appropriate biological interpretation of the immune response.

TORONTO, Ontario (PRWEB) April 06, 2021

There are many considerations for Immunology and Immunotoxicology (I&I) assessments that are needed during the early phase of drug development. This talk will outline when to consider different I&I assay services and the regulatory and scientific considerations for these that will influence the appropriate biological interpretation of the immune response.

Register for this live webinar taking place on Monday, April 19, 2021 at 9am EDT (2pm BST/UK) to hear a talk given by experts from Covance by Labcorp, James Munday, PhD, EU Lead, Immunology & Immunotoxicology; and Chris Cooper, Subject Matter Expert, Manager. They will give an outline of how to perform the appropriate safety assessments to show that there is no adverse immunotoxicology associated with the development of new therapeutic entities.

For more information, or to register for this event, visit Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:Ayesha RashidTel: +1 (416) 977-6555 x 272Email: arashid@xtalks.com

Share article on social media or email:

Excerpt from:
Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development, Upcoming Webinar Hosted by Xtalks - PR Web

Chronic Itching: The Crossroads of the Nervous and Immune Systems – Genetic Engineering & Biotechnology News

While many of us get that dry, itchy skin in the wintertime, those that suffer from eczemaatopic dermatitis (AD) as it is clinically knownhave chronic skin itching that is on a whole different level. Approximately 9.6 million children and 16.5 million adults in the U.S. have AD, which can have a serious effect on the quality of life for patients. AD has often been called the itch that rashes. Often, the itch begins before the rash appears, and, in many cases, the itchiness of the skin condition never really goes away. Now, a new study from investigators at Brigham and Womens Hospital and Harvard Medical School (HMS) published in The Proceedings of the National Academy of Sciences, offers new clues about the underlying mechanisms of itch. The new findings suggest a key molecular player known as cysteine leukotriene receptor 2 (CysLT2R) that may be a new target for intractable chronic itch.

In atopic dermatitis, the itching can be horrific, and it can aggravate disease, said co-corresponding author K. Frank Austen, MD, a senior physician in the Division of Allergy and Clinical Immunology at the Brigham. Austen is also the AstraZeneca Professor of Respiratory and Inflammatory Diseases, Emeritus, at Harvard Medical School. We began collaborating for two reasons: one is an interest in scienceI wandered into the study of what is now the cysteine leukotriene pathway decades ago, and Ive been pursuing it ever since. The second reason is itchunderstanding its cause and connections to neurons.

Austen and his lab, which focuses on the molecular components that contribute to allergic inflammation, collaborated with Isaac Chiu, PhD, an assistant professor of Immunology at Harvard Medical School. The team also included researchers at the Center for Immunology & Inflammatory Diseases at Massachusetts General Hospital and at the University of Texas at Dallas.

As a neuro-immunologist, Im interested in how the nervous system and immune system cross-talk, said Chiu, co-corresponding author of the study. Itch arises from a subset of neurons, and acute itch may be a protective response to help us remove something thats irritating the skin. However, chronic itch is not protective and can be pathological. The underlying mechanism that activates neurons and causes chronic itch is not well understood and new treatment is needed.

Chiu, Austen, and colleagues set out to elucidate the molecular mechanisms that may trigger chronic itch. To do so, they looked for gene activity in dorsal root ganglia (DRG) neurons linked to itch in mice. They found a striking level of CysLT2R, which was uniquely and highly expressed in these specific neurons. They also found expression of this receptor in human DRG neurons. This led the researchers to focus their analysis on the receptors role in itch signaling. Additional studies showed that activating this receptor-induced itching in a mouse model of AD, but not in other mouse models. Mice that lacked CysLT2R showed decrease itching. Collectively, their findings pointed to the receptors key role in causing itch and potentially contributing to AD.

Lead author Tiphaine Voisin, PhD, carried out many of the preclinical experiments in mouse models of AD during her time in the Chiu lab at HMS.

The last ten years or so of research in the field of chronic itch have shown the importance and the complexity of the interactions between the immune system and the nervous system, said Voisin. It was very exciting to explore the contribution of cysteine leukotrienes in these neuro-immune cross-talks leading to itch, including in a mouse model of AD.

Leukotrienes are a class of lipid molecules that originate from white blood cells, such as mast cells, which are involved in allergy and inflammation. Today, the leukotriene inhibitor montelukast, which targets CysLT1R, is used to treat asthma but does not provide relief from itch. No clinically approved inhibitors of CysLT2R currently exist and, while the researchers have seen evidence of the receptors in humans until an inhibitor is developed and trialed in humans, it will remain an open question as to whether the new target can lead to a therapy for patients.

While Chiu and Austen are eager to see their findings prompt treatment improvements, Austen, who has been pursuing leukotrienes since the 1970s, also notes the importance of making new discoveries and unexpected connections through research.

I do believe that science is bottom-up, not top-down, said Austen. The joy of research is doing it for the pleasure of finding out something you didnt know. The immune system is far more complex than we give it credit for. Understanding the involvement of nerves is an immense step forwardits been a missing piece in the study of inflammation. In my view, this is immensely important to connect neuroscience with those of us committed to studying inflammation.

Excerpt from:
Chronic Itching: The Crossroads of the Nervous and Immune Systems - Genetic Engineering & Biotechnology News

Board grants faculty appointments, promotions, tenure | The Source | Washington University in St. Louis – Washington University in St. Louis Newsroom

At the Washington University in St. Louis Board of Trustees meeting March 5, numerous faculty members were appointed or promoted with tenure or granted tenure, effective July 1 unless otherwise indicated.

Ruopeng An to associate professor at the Brown School;

Arpita Bose to associate professor of biology in Arts & Sciences;

Hong Chen to associate professor of biomedical engineering at the McKelvey School of Engineering;Francesco Di Plinio to associate professor of mathematics in Arts & Sciences;

Ali Hassan Ellebedy to associate professor of pathology and immunology at the School of Medicine;

Daniel S. Epps to professor of law at the School of Law;

Vanessa Duffy Fabbre to associate professor at the Brown School;

Roman M. Garnett to associate professor of computer science and engineering at the McKelvey School of Engineering;

Joseph P. Gaut to professor of pathology and immunology at the School of Medicine;

Jonathan Hanahan to associate professor of art at the Sam Fox School of Design & Visual Arts;

Erik A. Henriksen to associate professor of physics in Arts & Sciences;

Brendan A. Juba to associate professor of computer science and engineering at the McKelvey School of Engineering;

I-Ting Angelina Lee to associate professor of computer science and engineering at the McKelvey School of Engineering;

Diane Wei Lewis to associate professor of film and media studies in Arts & Sciences;

Ta-Chiang Liu, MD, PhD, to associate professor of pathology and immunology at the School of Medicine (tenure effective March 5);

Sojung Park to associate professor at the Brown School;

Rachel E. Sachs to professor of law at the School of Law;

Keith E. Schnakenberg to associate professor of political science in Arts & Sciences;

Elijah J. Thimsen to associate professor of energy, environmental and chemical engineering at the McKelvey School of Engineering;

Daniel Lyndon Jaffe Thorek to associate professor of radiology at the School of Medicine (tenure effective March 5); and

Xuan Zhang to associate professor of electrical and systems engineering at the McKelvey School of Engineering.

Peter Brunner as associate professor of neurological surgery at the School of Medicine (tenure effective March 5);

Claudia Swan as professor of art history in Arts & Sciences (tenure effective March 5); and

Jon T. Willie, MD, PhD, as associate professor of neurological surgery at the School of Medicine (tenure effective March 5).

Jeremy Bertomeu as associate professor of accounting (tenure effective March 5).

See the original post here:
Board grants faculty appointments, promotions, tenure | The Source | Washington University in St. Louis - Washington University in St. Louis Newsroom